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W
ithin the past year, providers caring for a
patient with cardiovascular disease and dia-
betes have been made to realize that despite
the associations of hyperglycemia and car-
diovascular complications, the results from the prospec-
tive studies evaluating aggressive glycemic intervention
did not follow the predicted script! Speciﬁcally, the ran-
domized clinical trials that addressed the question of
cardiovascular disease and glycemic control (i.e., Action
to Control Cardiovascular Risk in Diabetes [ACCORD],
Action in Diabetes and Vascular Disease: Preterax and
Diamicron Modiﬁed Release Controlled Evaluation
[ADVANCE], and Veterans Affairs Diabetes Trial [VADT])
provided results that suggest we take a closer look at the
“one size ﬁts all” glycemic target for A1C that has been
suggested in the past (1–3). Is it really surprising that we
have a similar situation with hyperglycemia and critically
ill patients in the intensive care unit (ICU) setting? For
years, it has been recognized that hyperglycemia has been
associated with mortality in critically ill patients as ob-
served across many cohorts, and as such, there has been
intense interest in evaluating the clinical effect of normal-
izing glycemia in these critically ill subjects (4–7). How-
ever, the recently reported observations from the
Normoglycemia in Intensive Care Evaluation-Survival Us-
ing Glucose Algorithm Regulation (NICE-SUGAR) trial
suggest that attempts to normalize glycemia are not the
simple answer to the problem (7).
The NICE-SUGAR study was a multicenter, interna-
tional, and randomized trial that evaluated the effect of
intensive versus conventional glucose control on out-
comes in hyperglycemic, critically ill subjects. After sub-
jects were identiﬁed in the ICU setting, they were
randomized either to tight glycemic control, deﬁned as a
target blood glucose level of 80–108 mg/dl, or to conven-
tional glycemic control, deﬁned as a blood glucose level in
the range of 144–180 mg/dl. Control for each group was
achieved by intravenous infusion of insulin. The time-
weighted blood glucose level achieved was 115 mg/dl in
the intensive group and 144 mg/dl in the conventional
group. The primary outcome was death from any cause
within 90 days of randomization. The key ﬁnding from
the study was that the mortality rate at 90 days was 3%
higher in the intensive treatment group, essentially
representing an 10% increase from intensive glycemic
intervention (7).
The NICE-SUGAR study had many strengths. These
strengths included the large number of subjects evaluated
(3,000 in each group) and the uniform insulin infusion
protocol that was implemented across all centers partici-
pating. The patients enrolled were clearly representative
of patients commonly seen in ICU settings and included
those admitted for operative procedures or for a wide
range of cardiovascular, hepatic, or renal abnormalities.
An additional strength was the choice of the primary
outcome, i.e., death, given that there would be no question
regarding adjudication. Of course, every study can be
suggested to have weaknesses, and the NICE-SUGAR
study was no different. However, the evaluation of out-
comes resulting from a carefully controlled intervention in
ICU patients, given the inherent heterogeneity in patient
presentation and response, is not a trivial task. The fact
that such a study was conducted in a complicated and
varied cohort and completed as an international study
with a standardized approach is impressive in itself, and
the authors should be congratulated.
The results from the NICE-SUGAR trial do raise addi-
tional questions and warrants in comparison with and in
contrast to those of Van den Berghe et al. (4,5), particu-
larly because the NICE-SUGAR results contradict the
ﬁndings of the prior studies (4,5,7). In addition, a paradigm
shift to institute intensive glycemic control measures in
ICU settings appeared to have had its genesis based on the
results of the studies of Van den Berghe et al. The apparent
differences between the studies may or may not have
played a role in the different outcomes. For example, the
studies of Van den Berghe et al. reported ﬁndings from a
single study site, and there may have been unique aspects
of treatment and characteristics in that population as
opposed to in a multicenter, international study with a
cohort with other characteristics. There were also differ-
ences in how nutritional therapy was provided, e.g., par-
enteral versus enteral. Perhaps the most important
differences, however, were the levels at which interven-
tion was directed. For example, in the studies of Van den
Berghe et al., insulin was initiated in the conventional
treatment group only if the blood glucose level exceeded
215 mg/dl, and the infusion was adjusted to maintain the
level at a value between 180 and 200 mg/dl. Although the
morning blood glucose level was maintained at a mean 
SD value of 153  33 mg/dl, the investigators reported that
only 39% of the patients treated with the conventional
approach received insulin and that their mean blood
glucose level was 173  33 mg/dl compared with 140  25
mg/dl in the patients who did not receive insulin (4). In the
NICE-SUGAR trial, 69% of subjects in the conventional
treatment group received insulin and, as would be ex-
pected, 97% of subjects in the intensive treatment group
received insulin (7). Thus, between the two studies, there
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insulin. Hypoglycemia for both the NICE-SUGAR trial and
the studies of Van den Berghe et al. was much greater in
the intensive treatment groups and was deﬁned as a blood
glucose level of 40 mg/dl. Whereas hypoglycemia oc-
curred in 5 and 1% of patients in the intensive treatment
group versus conventional treatment group in the studies
of Van den Berghe et al., hypoglycemia was reported in 6.8
and 0.5% of patients, respectively, in the NICE-SUGAR
study (4,7).
The most relevant questions to ask, however, are as
follows: What will be the implications of the NICE-SUGAR
results for the vast majority of patients with hyperglyce-
mia in the ICU? Are there speciﬁc subgroups of patients
that perhaps beneﬁted from this intervention? Is there a
beneﬁt derived from longer stays in the ICU? What were
the mechanisms for the observations? We simply do not
know why there was increased mortality in the intensive
insulin group, but we could argue that the adverse effect
was related to intensive insulin treatment, hypoglycemia,
or mechanisms yet undeﬁned. Given the emerging data on
the multiple mechanisms by which hypoglycemia can
adversely affect cardiovascular disease and knowing the
difﬁculty in detecting neuroglycopenia in the critically ill
patient, we need to further evaluate the impact of hypo-
glycemia in the ICU setting and its effect on outcomes
(8,9). An intriguing question yet to be answered is whether
intensive glycemic control can be achieved without signif-
icant hypoglycemia (e.g., use of continuous monitoring)
and whether achieving tight glycemic control without
hypoglycemia would have altered outcomes. In regard to
intensive insulin therapy, could it have impacted molecu-
lar mechanisms that are critical for tissue repair? For
example, the term “autophagy” refers to a major catabolic
pathway by which cells degrade and recycle macromole-
cules and organelles, and the process plays a critical role
in removing damaged cellular structures to keep the cell
healthy (10). Autophagy is inhibited by insulin; thus,
theoretically, high insulin concentrations might constrain
cellular repair. We also know that critical illnesses, such as
those conditions seen in the ICU (i.e., sepsis, trauma, etc.),
are accompanied by increased cell death (11). Therefore,
is it plausible to postulate that intensive insulin may have
impaired tissue remodeling and repair in this critically ill
population but perhaps not in clinical situations (e.g.,
outpatient settings) where this process may be more in
balance? This may be a prime example of a situation
where an understanding of the molecular biology of apo-
ptosis and of how therapeutic interventions modulate the
process in critical illness is direly needed. This informa-
tion could have great clinical relevance.
Given this data, do we now abandon our attempts at
intensive control in the ICU or, for that matter, not worry
about glycemic control in hospitalized settings? Should the
energy spent by hospitals to develop an infrastructure to
allow glucose monitoring and insulin algorithms be con-
sidered wasted? Clearly, if this happens, this will be a
“knee jerk” reaction. What we do know is that intensive
glycemic control to essentially normal levels with insulin
infusion in ICU patients did not improve but perhaps
worsened mortality compared with more moderate glyce-
mic targets: achieving a range of 144–180 mg/dl and
avoiding signiﬁcant hypoglycemia. This is an important
point that does not imply that we now accept glycemic
levels of 200 mg/dl and revert back to days of ignoring
glycemic levels and relying on sliding-scale regimens. This
is clearly not what the ﬁndings of the NICE-SUGAR trial
suggest. Until we know the answers, we simply need to
accept that our glycemic goals in the ICU should be more
moderate, e.g., 140–180 mg/dl. To suggest a totally differ-
ent paradigm now and to revert back to the level of care in
the past would simply be an overreaction to this important
study.
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